Multidisciplinary Approach to Patient with Malignant Melanoma
Giuseppina Della Vittoria Scarpati,
The incidence of melanoma is rapidly increasing worldwide and the prognosis of patients with metastatic disease is still poor,
with a median survival of 8–9 months and a 3-year overall survival (OS) rate less than 15% [1,2].
A complete surgical excision is the main treatment for primary cutaneous melanoma , but controversies about the extension of
excision margins still remain .
Sentinel lymph node biopsy (SLNB) provides important prognostic and staging data by the identification of regional node-negative
patients who would not benefit from a complete nodal dissection. However, there is no consensus in the definition of melanoma thickness
to enforce the execution of the SLNB .
To date, Interferon-α (IFN-α)is the only approved adjuvant treatment after surgical excision of high-risk melanoma, but its indication
remains still controversial [2,6].
Keywords: Melanoma, immunotherapy, B-RAF inibithors, chemotherapy.
Rights & PermissionsPrintExport